Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Short Bowel Syndrome
Interventions
DRUG

Glepaglutide

Glepaglutide will be delivered in a single-use autoinjector.

Trial Locations (19)

20007

Georgetown University Medical Center, Washington D.C.

53127

Universitätsklinikum Bonn, Bonn

55905

Mayo Clinic College of Medicin, Rochester

68198

University of Nebraska Medical Center, Omaha

68198-3285

Vanderbilt University Medical Center, Nashville, Nashville

Unknown

Universitair Ziekenhuis Leuven, Leuven

Rigshospitalet, Copenhagen

Hôpital Beaujon, Clichy

Centre Hospitalier Lyon-Sud, Pierre-Bénite

Charité - Universitätsmedizin Berlin, Berlin

Universitätsklinikum Frankfurt, Frankfurt

Asklepios Kliniken Hamburg GmbH, Hamburg

Universitätsmedizin Rostock, Rostock

UMC Radboud Nijmegen, Nijmegen

Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi, Lodz

Szpital Skawina sp. z o.o. im. Stanley Dudricka, Skawina

St Mark's Hospital, Harrow

UCLH Foundation NHS Trust, London

Norfolk and Norwich University Hospitals, Norwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zealand Pharma

INDUSTRY